Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06384807 · ClinicalTrials.gov registry record · Phase 1
A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors
A Phase 1 study of Solid Tumor, sponsored by Biohaven Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 500
- Enrollment target
- 17
- Study locations
NCT06384807: Recruiting Phase 1 study of Solid Tumor, sponsored by Biohaven Therapeutics.
NCT06384807 is a Phase 1 study of Solid Tumor that is actively recruiting participants, run by Biohaven Therapeutics. The registered enrollment target is 500 participants, above the 219-participant average among 196 other Solid Tumor trials with a reported enrollment target (128% higher). The trial reports 17 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06384807, a Phase 1 study of Solid Tumor, is actively recruiting participants, sponsored by Biohaven Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 500 participants
- Enrollment target
- 17
- Study locations
Study Summary
This is a Phase 1/2, first in human (FIH), open-label, multicenter study of BHV-1510 monotherapy and in Combination with Cemiplimab in participants with previously treated, advanced solid tumors.
Primary Outcome
Description: Incidence and severity of AEs, serious adverse events (SAEs) and dose limiting toxicities (DLTs). Severity of AEs will be assessed according to the NCI CTCAE v5.0. This applies to both the BHV-1510 monotherapy arm and BHV-1510 in combination with Cemiplimab arm.
Conditions Studied
Interventions
- DRUG Cemiplimab
- DRUG BHV-1510
Study Locations (17)
California
- Site-113 - Duarte
- Site-112 - La Jolla
- Site-111 - Palo Alto
Florida
- Site-103 - Miami
- Site-105 - Orlando
- Site-115 - Tampa
District of Columbia
- Site-114 - Washington D.C.
Georgia
- Site-110 - Augusta
Michigan
- Site-109 - Detroit
Missouri
- Site-101 - St Louis
New York
- Site-117 - New York
Oklahoma
- Site-116 - Oklahoma City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2024-04-22 |
| Est. Completion | 2028-02 |
| Phase | Phase 1 |
What NCT06384807 shows while recruiting
NCT06384807 is an interventional study that assigns participants to a tested intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, above the 219-participant average among 196 other Solid Tumor trials with a reported enrollment target (128% higher).
The record links to 1 condition, with Solid Tumor appearing as the primary indexed condition, and to 2 interventions - of which Cemiplimab is the first listed.
NCT06384807 lists 17 locations in 13 states (California, Florida, District of Columbia).
Frequently Asked Questions
What is clinical trial NCT06384807 about?
NCT06384807 is a clinical study titled "A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors". This is a Phase 1/2, first in human (FIH), open-label, multicenter study of BHV-1510 monotherapy and in Combination with Cemiplimab in participants with previously treated, advanced solid tumors.
What is the current status of trial NCT06384807?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 500 participants. The study started on 2024-04-22. Estimated completion is 2028-02.
What conditions does trial NCT06384807 study?
This clinical trial studies the following conditions: Solid Tumor.
What interventions are being tested in trial NCT06384807?
The interventions under investigation include: Cemiplimab (DRUG), BHV-1510 (DRUG).
Who is sponsoring clinical trial NCT06384807?
This trial is sponsored by Biohaven Therapeutics, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06384807 being conducted?
This trial has 17 study locations across California, District of Columbia, Florida, Georgia, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06384807's enrollment target sits among peer trials
500 10th of 196 higher than 187 of 196 other Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
-
Concurrent Azeliragon With Craniospinal Irradiation
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI